Cargando…
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
PURPOSE: While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to inve...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843742/ https://www.ncbi.nlm.nih.gov/pubmed/26323641 http://dx.doi.org/10.4143/crt.2015.155 |
_version_ | 1782428679286030336 |
---|---|
author | Yi, Jun Ho Kang, Jung Hun Hwang, In Gyu Ahn, Hee Kyung Baek, Hyun Jin Lee, Soon Il Lim, Do Hyoung Won, Young-Woong Ji, Jun Ho Kim, Hyo Song Rha, Sun Young Oh, Sung Yong Lee, Kyung Eun Lim, Taekyu Maeng, Chi Hoon Kim, Moon Jin Kim, Seung Tae Lee, Jeeyun Park, Joon Oh Park, Young Suk Lim, Ho Yeong Kang, Won Ki Park, Se Hoon |
author_facet | Yi, Jun Ho Kang, Jung Hun Hwang, In Gyu Ahn, Hee Kyung Baek, Hyun Jin Lee, Soon Il Lim, Do Hyoung Won, Young-Woong Ji, Jun Ho Kim, Hyo Song Rha, Sun Young Oh, Sung Yong Lee, Kyung Eun Lim, Taekyu Maeng, Chi Hoon Kim, Moon Jin Kim, Seung Tae Lee, Jeeyun Park, Joon Oh Park, Young Suk Lim, Ho Yeong Kang, Won Ki Park, Se Hoon |
author_sort | Yi, Jun Ho |
collection | PubMed |
description | PURPOSE: While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. MATERIALS AND METHODS: Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. RESULTS: A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). CONCLUSION: While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer. |
format | Online Article Text |
id | pubmed-4843742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-48437422016-05-06 A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi, Jun Ho Kang, Jung Hun Hwang, In Gyu Ahn, Hee Kyung Baek, Hyun Jin Lee, Soon Il Lim, Do Hyoung Won, Young-Woong Ji, Jun Ho Kim, Hyo Song Rha, Sun Young Oh, Sung Yong Lee, Kyung Eun Lim, Taekyu Maeng, Chi Hoon Kim, Moon Jin Kim, Seung Tae Lee, Jeeyun Park, Joon Oh Park, Young Suk Lim, Ho Yeong Kang, Won Ki Park, Se Hoon Cancer Res Treat Original Article PURPOSE: While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. MATERIALS AND METHODS: Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. RESULTS: A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). CONCLUSION: While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer. Korean Cancer Association 2016-04 2015-08-10 /pmc/articles/PMC4843742/ /pubmed/26323641 http://dx.doi.org/10.4143/crt.2015.155 Text en Copyright © 2016 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Yi, Jun Ho Kang, Jung Hun Hwang, In Gyu Ahn, Hee Kyung Baek, Hyun Jin Lee, Soon Il Lim, Do Hyoung Won, Young-Woong Ji, Jun Ho Kim, Hyo Song Rha, Sun Young Oh, Sung Yong Lee, Kyung Eun Lim, Taekyu Maeng, Chi Hoon Kim, Moon Jin Kim, Seung Tae Lee, Jeeyun Park, Joon Oh Park, Young Suk Lim, Ho Yeong Kang, Won Ki Park, Se Hoon A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology |
title | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology |
title_full | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology |
title_fullStr | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology |
title_full_unstemmed | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology |
title_short | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology |
title_sort | retrospective analysis for patients with her2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: in the perspectives of ethnicity and histology |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843742/ https://www.ncbi.nlm.nih.gov/pubmed/26323641 http://dx.doi.org/10.4143/crt.2015.155 |
work_keys_str_mv | AT yijunho aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kangjunghun aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT hwangingyu aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT ahnheekyung aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT baekhyunjin aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT leesoonil aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT limdohyoung aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT wonyoungwoong aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT jijunho aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kimhyosong aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT rhasunyoung aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT ohsungyong aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT leekyungeun aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT limtaekyu aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT maengchihoon aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kimmoonjin aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kimseungtae aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT leejeeyun aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT parkjoonoh aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT parkyoungsuk aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT limhoyeong aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kangwonki aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT parksehoon aretrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT yijunho retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kangjunghun retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT hwangingyu retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT ahnheekyung retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT baekhyunjin retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT leesoonil retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT limdohyoung retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT wonyoungwoong retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT jijunho retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kimhyosong retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT rhasunyoung retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT ohsungyong retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT leekyungeun retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT limtaekyu retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT maengchihoon retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kimmoonjin retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kimseungtae retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT leejeeyun retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT parkjoonoh retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT parkyoungsuk retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT limhoyeong retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT kangwonki retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology AT parksehoon retrospectiveanalysisforpatientswithher2positivegastriccancerwhoweretreatedwithtrastuzumabbasedchemotherapyintheperspectivesofethnicityandhistology |